Lilly aims to better match the demographic composition of clinical test groups with the disease prevalence rate in the general population. sites in the northeast 95 sites in the southeast 5 sites in alaska and hawaii 10 A “diverse clinical site” is defined as any clinical-trial site where the patient population (of the medical practice, not necessarily who they enroll into trials) is more than 25 percent non-Caucasian.